Ten antiangiogenic drugs targeting VEGF or its receptors are approved for cancer treatment.
However, these agents, intended to block tumors' blood supply, may cause hypoxia, which …

Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly
type of primary malignant brain tumor, with a patient's median survival rate ranging from 15 …

Unfortunately, the increased hydrodynamic and steric hindrance resulting from the smaller
vessel pores caused by normalization may compromise the advantage gained from …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of
glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic …

Simple Summary Glioblastoma multiforme (GBM) is the most aggressive tumor type in the
central nervous system. Hypoxia, defined as a lack of sufficient oxygen in tissues, is the most …

Pathological angiogenesis—driven by an imbalance of pro-and antiangiogenic signaling—
is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in …

Integrins are heterodimeric cell surface receptors that bind to different extracellular ligands
depending on their composition and regulate all processes which enable multicellular life. In …

Integrins belong to a large family of αβ heterodimeric transmembrane proteins first
recognized as adhesion molecules that bind to dedicated elements of the extracellular …

Hypoxia is a salient feature of most solid tumors, and hypoxic adaptation of cancer cells has
crucial implications in propagation of malignant clonal cell population. Osteopontin (OPN) …